Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the nivolumab prostate cancer study is displayed, including its study design, eligibility criteria, locations, outcome measures, and posted results information.
    Difference
    54%
    Check dated 2026-11-08T01:47:22.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T21:55:13.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during a transition.
    Difference
    1%
    Check dated 2026-10-24T22:22:05.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer's displayed ClinicalTrials.gov revision changes from v3.7.1 to v3.7.2. The page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:24:11.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:17:19.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error page, replacing the expected content. The 403 content and site chrome are displayed instead of the expected study details.
    Difference
    0.5%
    Check dated 2026-09-26T21:56:26.000Z thumbnail image

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.